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Colorectal carcinoma is the second most common malignancy in western countries. The overall
five-year survival rate for this malignancy is about 45%. The prognosis depends markedly on
the extent of disease at time of diagnosis: patients with a carcinoma restricted to the bowel wall
have a 5-year survival of 90Vo, but those patients with distant metastases have a median
survival of 10.5 months. In selected patients with liver metastases urgical removal of these
metastases results in prolonged survival. If such options are not possible, these patients may
be offered systemic chemotherapy. Among the numerous drugs tested, the fluorinated
pyrimidine 5-fluorouracil (5-FU) is the most active agent. However, only 10-20% of Íhe
patients will respond to monotherapy 5-FU and effects on survival are discouraging low.
Therefore, reducing the mortality from colorectal cancer should be aimed at prevention,
screening leading to earlier detection, and better chemotherapeutic regimens. This thesis is
focused on ways of enhancing 5-FU based chemotherapy.
In chapter I the general outlines of this thesis are described, with emphasis on the mechanism
of cytotoxicity of 5-FU.
In chapter 2 an update is given of recent developments in the field of colorectal carcinoma.
The past decade has provided growing insight into three basic components of cancer genetics:
oncogenes, tumor suppressor genes and the concept that malignant cells arise from genetic
alteration of a normal cell. The formation of colon adenomas and carcinomas appears to be
associated with a series of such genetic alterations. The familial polyposis coli gene is thought
to be responsible for the development of adenomas from normal mucosa. Subsequent
chromosomal changes leading to development of carcinoma may be caused by environmental
mulagens. In addition to this genetic theory, numerous risk factors for developing colorectal
cancer have been identified. These risk factors are associated with an increased proliferative
state of the entire colonic mucosa. These proliferation changes may precede colorectal cancer.
It has also been suggested that reduction of the mitotic changes may prevent cancer. However,
its exploitation in reducing cancer risks will take considerable efforts in clinical practice.
Screening is aimed on detection ofearlier stages ofcolorectal cancer, but the costs of screening
the average population are high, and therefore screening is still a controversial issue. The
mucosal proliferation rate, preneoplastic gene expression and genetic screening may in future
be useful to determine a subgroup eligible for intensive screening strategies.
The finding of a 30%a survival advantage in patients with colon cancer penetrating the bowel
wall with affected lymph nodes (Dukes C) receiving 5-FU plus levamisol has been a major step
forward. Whether this regimen or other 5-FU based adjuvant therapies will be the most
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carcinoma (no affected lymph nodes), will in the near future more clearly be established.
Presently, locoregional colorectal cancer may be considered a disease benefitting surgical
adjuvant therapy.
The developments discussed in this chapter may have far reaching consequences for the
prevention, early detection and early chemotherapeutic treatment of colorecíal cancer. Each of
these developments may be a step ahead in the reduction of mortality of this disease.
Chapter 3 contains the results of a phase II study of 5-FU continuous infusion 600 mglmzl24
hours day 1-4 preceded by a high dose methotrexate 1,500 mglmz rapid infusion in patients
with advanced colorectal carcinoma. In 2l patients who had not been treated previously with
other chemotherapeutic agents, an overall response rate of 20% was observed. Twelve patients
with progression of tumor during this chemotherapy regimen, subsequently received the same
dose of 5-FU combined with daily leucovorin 200 mglm2 i.v. on day l-4. Two out of these 12
patients had stabilization of tumor growth. Mucositis grade l-2 occurred in 50% of patients
during both regimens. Other toxicities were limited, the chemotherapy was well tolerated.
Median survival of the 2l patients was l0 months. It was concluded that high dose
methotrexate combined with 5-FU continuously infused has activity in colon cancer. However,
the response rate is still low and improvement of survival is unlikely to occur. The observation
of stabilization of disease after substituting methotrexate by leucovorin underlines the
differences in 5-FU modulation. but its clinical value for patients resistant o methotrexate plus
5-FU is clearly limited.
In chapter 4 a phase I and phase II study of 14 days continuous infusion of 5-FU combined
with weekly leucovorin is described. Prolonged infusion of a cytostatic drug allows exposure
of tumor cells over the course of one or more doubling times. In patients with metastatic
colorectal cancer, treatment with continuously infused 5-FU results in improved response rates
and decrease side effects as compared to bolus injection 5-FU. Leucovorin addition to 5-FU
diminishes resistance to this drug by providing reduced folates, necessary for increasing
fluoropyrimidine mediated thymidylate synthase inhibition (see also Figure 1, chapter 1).
Several clinical studies in patients with colorectal cancer treated with s-Fu/leucovorin
demonstrated not only improved response rates but also improved survival. In the present study
both adaptations (continuous infusion and co-treatment with leucovorin) are combined. The
phase I study was performed to establish the maximum toierated dose of a weekly intravenously
administered leucovorin injection when combined with a 5-FU dose of 300 mglmzl24 hours
continuously infused for 14 days. Courses were repeated every four weeks. The addition of any
dose of leucovorin starting with 20 mg/m2 to this 5-FU dose resulted in an unexpectedly high
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toxicity. Therefore, we decided to lower the 5-FU dose to 200 mglm2l24 hours for 14 days.
It appeared feasible to combine this with a weekly bolus injection of 200 mglmz leucovorin.
At this dose level 2l patients with metastatic colorectal cancer were treated. None of these
patients received prior chemotherapy. In these 21 patients one patient had a complete response
(disappearance ofall perceptible tumor) and four patients had a partial response (at least 50%
reduction of largest lesion with no progression of other lesions). This gives a response rate of
24Vo. Toxícity of this regimen was low: mucositis WHO grade l-2 was most frequent, and
observed in 32% of chemotherapy courses. It was concluded that this continuous infusion
regimen has comparable antitumor response to other 5-FU/leucovorin regimens in colorectal
carcinoma. This regimen has minimal toxicity.
As described above, the effect of leucovorin on the fluoropyrimidines 5-FU and 5-fluoro-
2'deoxyuridine (FUdR) has a well known basis: increasing the degree and retention of
fluoropyrimidine mediated inhibition of a key enzyme in DNA synthesis (thymidylate synthase)
(see Figure 2, chapter 1). Synergism has also been described between 5-FU and a-interferon.
The mechanism has not yet been elucidated, but may also be mediated by thymidylate synthase
inhibition, Besides, very limited data are available on combined effects of leucovorin and o-
interferon on fluoropyrimidines.
In chapter 5 the modulating effects of leucovorin and/or a-interferon were studied in the
human colorectal cancer cell lines SW 948 and COLO 320. Also thymidylate synthase levels
were studied in both cell lines, as well as the effects of 5-FU and o-interferon on this enzyme.
Although both cell lines have a colorectal cancer origin, striking differences were noted: the
SW 948 cell line was 11.7 fold more sensitive to 5-FU and 16.7 fold more sensitive to FUdR
compared to the COLO 320 cell line. Differences between fluoropyrimidine sensitivity
correlated with lower thymidylate synthase level in the more sensitive cell line. In COLO 320
modulation of 5-FU, either by leucovorin or by a-interferon was not possible. As leucovorin
did enhance FUdR activity in this cell line, it is conceivable that 5-FU mediated cytotoxicity
in COLO 320 is not primarily mediated by thymidylate synthase inhibition. In SW 948 addition
of leucovorin to 5-FU resulted in a2.4 fold lower IC5s (concentration 5-FU required to induce
50% growth inhibition), compared to 5-FU alone. cy-Interferon lowered the IC5o of 5-FU 6.8
fold in this cell line, and the IC56 on the combination 5-FU, leucovorin and cy-interferon was
11.2 fold lower as compared to 5-FU alone. In this cell line, the effects of both drugs on FUdR
were comparable, but less pronounced. Although direct effects of a-interferon on thymidylate
synthase could be excluded, evidence existed that cv-interferon, when combined with


































serve as a model for successful or failing modulation of 5-FU by leucovorin and/or o-
interferon. It may be possible to select sensitive or resistant umors by measuring thymidylate
synthase levels. The frnding that o-interferon can increase 5-FU/leucovorin mediated
cytotoxicity, justifies further study of the triple agent combination in phase I-II studies in
patients with advanced colorectal carcinoma.
In chapter 6 the toxicity (phase I study) and activity (phase II study) of the addition of o-
interferon to a 5-FU/leucovorin combination is described. We started the phase I study with
determining the optimal 5-FU dose (bolus injection, two consecutive days) when combined with
a fixed oral dose leucovorin (60 mg, 3 times daily). Thereafter, the optimal dose of 5-FU with
the same dose leucovorin, combined with 18.1d Units cv-interferon was established. The
modulating agents leucovorin and o-interferon were given for three days, starting one day
before 5-FU infusion and ending at the last day of 5-FU infusion. Chemotherapy was given
every two weeks. Serum levels of leucovorin and its active metabolite were measured in order
to hnd out whether the concentrations of these reduced folates were high enough to modulate
5-FU cytotoxicity. Besides, the influence of o-interferon on pharmacokinetic behaviour of
leucovorin could be studied by comparing the serum levels of reduced folates in patients treated
with and without a-interferon. The phase I study was followed by a phase II study of 5-
FU/leucovorin/cy-interferon at the established optimal dose of 5-FU in patients with
disseminated colorectal cancer who did not receive prior chemotherapy.
In the phase I study an optimal dose of 150 mglm2lday 5-FU was found for the 5-FU +
leucovorin combination. Dose limiting toxicities were mucositis, diarrhea and leucopenia.
Although o-interferon added its own toxicity (fever, flu like symptoms), it did not influence
the optimal dose of 5-FU. Pharmacokinetics of repeated oral dose of 60 mg leucovorin, started
one day before 5-FU infusion, revealed mean peak and through serum concentrations of
reduced folates high enough to modulate in vitro 5-FU cytotoxicity. Signifrcantly higher serum
levels were found after addition of a-interferon. Influence of o-interferon on gastrointestinal
absorption or on renal clearance of leucovorin could be excluded, and thus an effect of o-
interferon on (hepatic) metabolism ofleucovorin is probable. In the phase II study on the triple
drug combination a complete response was observed in 3 patients and a partial response in 12
out of 28 patients (response rate:15128 patients :54%). Median survival in this study was
16 months. Although the response rate is encouraging, median time to progression of
responding patients after completion of chemotherapy was only 20 weeks. The frequently
observed, sometimes severe, toxicity made prolonged treatment after eight chemotherapy
courses not feasible. In an attempt to increase resDonse duration. a less toxic maintenance
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therapy is now given to responding patients. This treatment is equal to the above described 3
day regimen, but it is given every six weeks in stead of every two weeks. It is concluded in
this chapter that this 5-FU/leucovorin/o-interferon combination seems active in metastatic
colorectal carcinoma. The pharmacokinetic interaction between o-interferon and leucovorin may
play a role in the activity of this regimen. Proof of superiority to other schedules requires
larger randomized trials.
In conclusion, the results of palliative chemotherapy for patients with disseminated colorectal
carcinoma can be improved. The effect of 5-FU, for decennia the only drug that occasionally
produced responses, can be augmented by at least two drugs: leucovorin and cy-interferon. On
the combination of 5-FU and leucovorin a small but significant improval of survival has been
demonstrated. The chemotherapy is compatible with a satisfactory quality of life by giving low
doses leucovorin or by giving the 5-FU as a prolonged infusion. On the combination of 5-FU
and a-interferon high response rates havebeen documented, and results ofphase III studies are
now awaited. The demonstration of increased S-FU/leucovorin mediated cytotoxicity after the
addition of o-interferon, and the observation of a high response rate on a 5-FU/leucovorin/o-
interferon combination (at the cost of high toxicity), indicates that further improvement of
treatment strategies for disseminated colorectal cancer may be in finding an optimal regimen
on this triple drug combination.
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